Structural Identification of Zotarolimus (ABT-578) Metabolites Generated by Human Liver Microsomes Using Ion-Trap and High-Resolution Time-of-Flight Mass Spectrometry in Combination with the Analysis of Fragmentation Patterns
Zotarolimus (ABT-578) is a sirolimus derivative that, like sirolimus and everolimus, is an inhibitor of cell growth via inhibition of the mechanistic target of rapamycin (mTOR). Zotarolimus was developed for coating coronary stents to prevent smooth muscle cell proliferation and restenosis. Albeit z...
Main Authors: | Touraj Shokati, Seth H. Drake, Wanzhu Zhao, Jost Klawitter, Jelena Klawitter, Uwe Christians |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-10-01
|
Series: | Metabolites |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-1989/13/10/1093 |
Similar Items
-
Comparison of 3-year clinical outcomes between Endeavor Resolute® and Resolute Integrity® zotarolimus-eluting stents in an Asian population
by: Yong Hoon Kim, et al.
Published: (2020-04-01) -
Anti-Cancer Effects of Zotarolimus Combined with 5-Fluorouracil Treatment in HCT-116 Colorectal Cancer-Bearing BALB/c Nude Mice
by: Geng-Ruei Chang, et al.
Published: (2021-08-01) -
The Anti-Cancer Effects of a Zotarolimus and 5-Fluorouracil Combination Treatment on A549 Cell-Derived Tumors in BALB/c Nude Mice
by: Ching-Feng Wu, et al.
Published: (2021-04-01) -
Five-Year Comparative Efficacy of Everolimus-Eluting vs. Resolute Zotarolimus-Eluting Stents in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
by: Endrin Koni, et al.
Published: (2021-03-01) -
role of liver /kiudney microsomal antibody type 1 with type 2-autoimmune hepatitis
by: Eman sh. Al- obeidy, et al.
Published: (2006-07-01)